BioSpace1d
Newleos Raises $93.5M to Advance Neuropsychiatric Cast-Offs from Roche
Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.
GlobalData on MSN1d
Newleos secures $93.5m for neuropsychiatric treatments
Newleos has closed an oversubscribed Series A financing round, raising $93.5m to revolutionise neuropsychiatric disorder ...
Longwood Fund launches anxiety drug developer with $93.5M investment
A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...
The Pharma Letter1d
Newleos emerges with $93.5 million and CNS drugs licensed from Roche
Boston, USA-based Newleos Therapeutics, a neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug ...
BioPharma Dive1d
A brain biotech launches with Roche’s spare parts
Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...
ENDPOINTS NEWS2d
Newleos, a new biotech with $93.5M, re­pur­pos­es Roche's ex­per­i­men­tal CNS drugs
Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, ...
MM&M1d
Rx Rundown: Novartis, Abcuro, SpringWorks Therapeutics and more
RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...